Home > Research > Publications & Outputs > Trial design for evaluating novel treatments du...

Links

Text available via DOI:

View graph of relations

Trial design for evaluating novel treatments during an outbreak of an infectious disease

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Trial design for evaluating novel treatments during an outbreak of an infectious disease. / Whitehead, John Raymond; Olliaro, Piero; Lang, Trudie; Horby, Peter W.

In: Clinical Trials, Vol. 13, No. 1, 02.2016, p. 31-38.

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

Vancouver

Author

Whitehead, John Raymond ; Olliaro, Piero ; Lang, Trudie ; Horby, Peter W. / Trial design for evaluating novel treatments during an outbreak of an infectious disease. In: Clinical Trials. 2016 ; Vol. 13, No. 1. pp. 31-38.

Bibtex

@article{d1bf2bf374c34f858f62a44a11a2a04a,
title = "Trial design for evaluating novel treatments during an outbreak of an infectious disease",
abstract = "Tragically, the outbreak of Ebola that started in West Africa in 2014 has been far more extensive and damaging than any previous outbreaks. The duration of the outbreak has, for the first time, allowed the clinical evaluation of Ebola treatments. This article discusses the designs used for two such clinical trials which have recruited patients in Liberia and Sierra Leone. General principles are outlined for trial designs intended to be deployed quickly, adapt flexibly and provide results soon enough to influence the course of the current epidemic rather than just providing evidence for use should Ebola break out again. Lessons are drawn for the conduct of clinical research in future outbreaks of infectious diseases, where the sequence of events may or may not be similar to the West African Ebola epidemic.",
author = "Whitehead, {John Raymond} and Piero Olliaro and Trudie Lang and Horby, {Peter W.}",
year = "2016",
month = feb,
doi = "10.1177/1740774515617740",
language = "English",
volume = "13",
pages = "31--38",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Trial design for evaluating novel treatments during an outbreak of an infectious disease

AU - Whitehead, John Raymond

AU - Olliaro, Piero

AU - Lang, Trudie

AU - Horby, Peter W.

PY - 2016/2

Y1 - 2016/2

N2 - Tragically, the outbreak of Ebola that started in West Africa in 2014 has been far more extensive and damaging than any previous outbreaks. The duration of the outbreak has, for the first time, allowed the clinical evaluation of Ebola treatments. This article discusses the designs used for two such clinical trials which have recruited patients in Liberia and Sierra Leone. General principles are outlined for trial designs intended to be deployed quickly, adapt flexibly and provide results soon enough to influence the course of the current epidemic rather than just providing evidence for use should Ebola break out again. Lessons are drawn for the conduct of clinical research in future outbreaks of infectious diseases, where the sequence of events may or may not be similar to the West African Ebola epidemic.

AB - Tragically, the outbreak of Ebola that started in West Africa in 2014 has been far more extensive and damaging than any previous outbreaks. The duration of the outbreak has, for the first time, allowed the clinical evaluation of Ebola treatments. This article discusses the designs used for two such clinical trials which have recruited patients in Liberia and Sierra Leone. General principles are outlined for trial designs intended to be deployed quickly, adapt flexibly and provide results soon enough to influence the course of the current epidemic rather than just providing evidence for use should Ebola break out again. Lessons are drawn for the conduct of clinical research in future outbreaks of infectious diseases, where the sequence of events may or may not be similar to the West African Ebola epidemic.

U2 - 10.1177/1740774515617740

DO - 10.1177/1740774515617740

M3 - Journal article

VL - 13

SP - 31

EP - 38

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 1

ER -